Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosis
ROIV•Phase 3 trial begins in cutaneous sarcoidosis
Roivant unit Priovant enrolled first patients in a Phase 3 trial of brepocitinib for cutaneous sarcoidosis, a condition with no approved therapies.
- Results will be presented in the future, with BEACON+ topline data expected in 2028.
- The study follows a positive Phase 2 outcome that supported FDA Breakthrough Therapy Designation, positioning brepocitinib as a potential new treatment option.
- Priovant expects a U.S. regulatory decision in dermatomyositis by end-September 2026, supporting a near-term launch path for the drug.
